Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of advanced breast cancer.
Orlando L, Colleoni M, Fedele P, Cusmai A, Rizzo P, D'Amico M, Chetri MC, Cinieri S. Orlando L, et al. Among authors: cusmai a. Ann Oncol. 2007 Jun;18 Suppl 6:vi74-6. doi: 10.1093/annonc/mdm230. Ann Oncol. 2007. PMID: 17591838 Free article. Review.
Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study.
Fedele P, Landriscina M, Moraca L, Cusmai A, Gnoni A, Licchetta A, Guarini C, Lanotte L, Pappagallo MN, Melaccio A, Giordano G, Maselli FM, Pinto A, Giuliani F, Chiuri V, Giotta F, Gadaleta-Caldarola G. Fedele P, et al. Among authors: cusmai a. Cancers (Basel). 2024 Oct 10;16(20):3442. doi: 10.3390/cancers16203442. Cancers (Basel). 2024. PMID: 39456537 Free PMC article.
Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study.
Fedele P, Landriscina M, Moraca L, Gadaleta-Caldarola A, Cusmai A, Giuliani F, Chiuri V, Giotta F, Pinto A, Mirisola V, Gadaleta-Caldarola G. Fedele P, et al. Among authors: cusmai a. J Clin Med. 2024 Dec 6;13(23):7441. doi: 10.3390/jcm13237441. J Clin Med. 2024. PMID: 39685899 Free PMC article.
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Ciccarese M, Fabi A, Moscetti L, Cazzaniga ME, Petrucelli L, Forcignanò R, Lupo LI, De Matteis E, Chiuri VE, Cairo G, Febbraro A, Giordano G, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Latorre A, Scavelli C, Romito S, Cusmai A, Palmiotti G, Surico G. Ciccarese M, et al. Among authors: cusmai a. Breast Cancer Res Treat. 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9. Epub 2017 Mar 28. Breast Cancer Res Treat. 2017. PMID: 28353061
Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer.
Rizzo A, Massafra R, Fanizzi A, Rinaldi L, Cusmai A, Latorre A, Zaccaria GM, Ronchi M, Telegrafo M, Gadaleta-Caldarola G, Giotta F, Lorusso V, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Expert Opin Investig Drugs. 2022 Jul;31(7):707-713. doi: 10.1080/13543784.2022.2078191. Epub 2022 May 18. Expert Opin Investig Drugs. 2022. PMID: 35575038
33 results